ALK-immunoreactive Neoplasms

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2012 Jul 19

PMID 22808292

Citations 17

Authors

Parham Minoo

Huan-You Wang

Affiliations

Soon will be listed here.

Abstract

Context: Since the first discovery of anaplastic lymphoma kinase (ALK) in anaplastic large cell lymphoma (ALCL) by Morris et al in 1994, the number of ALK-positive neoplasms, either in the form of translocation or gain-of-function mutations, have been dramatically expanded from ALCL of T- and NK-cell origin, to diffuse large B-cell lymphoma, inflammatory myofibroblastic tumor (IMT), neuroblastoma, non-small cell lung carcinoma (NSCLC), undifferentiated anaplastic thyroid carcinoma, and rare type of sarcomas.

Objective: This review covers the major aspects of ALK-immunoreactive neoplasms with emphasis on the pathogenesis of ALK-positive neoplasms. The new advances and rapid-evolving practices using ALK inhibitors for therapy are also discussed at the end of this review.

Data Sources: ALK(+) articles published in English literature are retrieved and critically reviewed.

Conclusion: ALK(+) neoplasia is a rapidly growing field and the list of ALK(+) neoplasms is being expanded continuously. Accurate and correct diagnosis of ALK(+) neoplasms is of paramount importance in guiding the appropriate treatment in the era of personalized medicine using specific ALK inhibitor.

Citing Articles

ALK-positive large B-cell lymphoma (ALK + LBCL) with aberrant CD3 expression.

Baker J, Zadeh S, Aguilera N J Hematop. 2024; 17(2):109-114.

PMID: 38573563 PMC: 11127819. DOI: 10.1007/s12308-024-00582-x.

Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials.

Wang K, Zhang Y, Xing Y, Wang H, He M, Guo R Discov Oncol. 2024; 15(1):50.

PMID: 38403820 PMC: 10894806. DOI: 10.1007/s12672-024-00904-6.

Malakoplakia with aberrant ALK expression by immunohistochemistry: a case report.

Zhang X, Li J, Chen S, Li Y, Wang H, He J Diagn Pathol. 2023; 18(1):97.

PMID: 37644531 PMC: 10464214. DOI: 10.1186/s13000-023-01383-z.

Endotracheal inflammatory myofibroblastic tumour: A rare cause of central airway occlusion in adults.

Lourdesamy Anthony A, Satnam Singh T, Ng K, Rahaman J Respirol Case Rep. 2022; 10(7):e0984.

PMID: 35702693 PMC: 9174595. DOI: 10.1002/rcr2.984.

Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments.

Latif M, Ashraf Z, Basit S, Ghaffar A, Zafar M, Saeed A RSC Adv. 2022; 8(30):16470-16493.

PMID: 35540549 PMC: 9080316. DOI: 10.1039/c8ra01934g.

References

Khoury J, Medeiros L, Rassidakis G, Yared M, Tsioli P, Leventaki V . Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res. 2003; 9(10 Pt 1):3692-9. View

Lamant L, Gascoyne R, Duplantier M, Armstrong F, Raghab A, Chhanabhai M . Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer. 2003; 37(4):427-32. DOI: 10.1002/gcc.10232. View

Marino-Enriquez A, Ou W, Weldon C, Fletcher J, Perez-Atayde A . ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer. 2011; 50(3):146-53. DOI: 10.1002/gcc.20839. View

Griffin C, Hawkins A, Dvorak C, Henkle C, Ellingham T, Perlman E . Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 1999; 59(12):2776-80. View

Bai R, Dieter P, Peschel C, Morris S, Duyster J . Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol. 1998; 18(12):6951-61. PMC: 109278. DOI: 10.1128/MCB.18.12.6951. View

Mino-Kenudson M, Chirieac L, Law K, Hornick J, Lindeman N, Mark E . A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010; 16(5):1561-71. PMC: 2831135. DOI: 10.1158/1078-0432.CCR-09-2845. View

Medeiros L, Elenitoba-Johnson K . Anaplastic Large Cell Lymphoma. Am J Clin Pathol. 2007; 127(5):707-22. DOI: 10.1309/r2q9ccuvtlrycf3h. View

Salido M, Pijuan L, Martinez-Aviles L, Galvan A, Canadas I, Rovira A . Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol. 2010; 6(1):21-7. PMC: 3359090. DOI: 10.1097/JTO.0b013e3181fb7cd6. View

Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath P . Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene. 2007; 26(38):5606-14. DOI: 10.1038/sj.onc.1210346. View

10.

Khoury J, Rassidakis G, Medeiros L, Amin H, Lai R . Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma. Blood. 2004; 104(5):1580-1. DOI: 10.1182/blood-2004-03-1151. View

11.

Mourali J, Benard A, Lourenco F, Monnet C, Greenland C, Moog-Lutz C . Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol Cell Biol. 2006; 26(16):6209-22. PMC: 1592804. DOI: 10.1128/MCB.01515-05. View

12.

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

13.

STEIN H, Foss H, Durkop H, Marafioti T, Delsol G, Pulford K . CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000; 96(12):3681-95. View

14.

Gu T, Tothova Z, Scheijen B, Griffin J, Gilliland D, Sternberg D . NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood. 2004; 103(12):4622-9. DOI: 10.1182/blood-2003-03-0820. View

15.

Amin H, Medeiros L, Ma Y, Feretzaki M, Das P, Leventaki V . Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene. 2003; 22(35):5399-407. DOI: 10.1038/sj.onc.1206849. View

16.

Bridge J, Kanamori M, Ma Z, Pickering D, Hill D, Lydiatt W . Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol. 2001; 159(2):411-5. PMC: 1850566. DOI: 10.1016/S0002-9440(10)61711-7. View

17.

Lin E, Li L, Guan Y, Soriano R, Rivers C, Mohan S . Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res. 2009; 7(9):1466-76. DOI: 10.1158/1541-7786.MCR-08-0522. View

18.

Pillay K, Govender D, Chetty R . ALK protein expression in rhabdomyosarcomas. Histopathology. 2002; 41(5):461-7. DOI: 10.1046/j.1365-2559.2002.01534.x. View

19.

Debelenko L, Arthur D, Pack S, Helman L, Schrump D, Tsokos M . Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest. 2003; 83(9):1255-65. DOI: 10.1097/01.lab.0000088856.49388.ea. View

20.

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H . Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131(6):1190-203. DOI: 10.1016/j.cell.2007.11.025. View